SA53 MDM2
Alternative Names: SA53-MDM2; SA53-OSLatest Information Update: 16 Sep 2024
At a glance
- Originator Lamassu Pharma
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Aug 2024 Lamassu Bio plans a phase I trial for Solid tumor (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) in Spetember 2024 (NCT06578624)
- 05 Aug 2024 SA53 MDM2 is available for licensing as of 05 Aug 2024. https://www.lamassupharma.com/
- 05 Aug 2024 Preclinical trials in Cancer in USA (unspecified route), before August 2024 (Lamassu Pharma website, August 2024)